Tuesday, November 1, 2011

Soda and Teen Violence: Hazards of Correlational Analysis Can Put Truth in Harm’s Way

Statistical Ammo for the Twinkie Offense: Guns Don’t Kill People, Soda Kills People?

No one with an interest in public health and a zest for social engineering can go wrong by criticizing soda. That particular cup runneth over with empty calories and plausible links to obesity, as well as tooth decay. The carbonated beverage industry is fighting a pitched battle in municipalities across the US to avoid punitive taxation meant to price soda beyond the reach of citizens who seem most at risk of making poor nutritional choices -- choices that ultimately all of us must pay for. No matter what you think of coercive taxation, it’s really hard to defend soda.

Now, though, thanks to research published by two Harvard-trained researchers, Sara Solnick of University of Vermont and David Hemenway of the Harvard School of Public Health, soda has come under another sort of fire.

An analysis performed on the Boston Youth Survey database shows a significant correlation between soda consumption and violence in teens, including a propensity to carry guns and exhibit violent behavior with partners. The paper, which appeared in the Journal of Injury Prevention, got a two-day flurry of press attention because it has a provocative thesis that keyed off the famous “Twinkie Defense.” It gives everyone even more reason to worry about what dangers may lurk in our refrigerators.

Or does it?

Friday, October 14, 2011

Challenging Bioethics of Organ Transplantation: ‘The Book of Jobs’ Raises New Moral Lessons

Gods of Technology Burden Us with Tough Moral Questions

In an uncharacteristic shift from the remote third-person voice of our typical posts, I want to begin by saying that my husband strongly advised me not to write this particular blog. Observing that Steve Jobs was being lionized, almost deified, by the press and public, he warned that no good could come of advancing the view that Steve Jobs’ transplant two and a half years ago, presumably after a Whipple resection, might potentially be a waste of a perfectly good liver.

Which is why, as I type this, I am fingering my adored iPhone (which I actually consider to be a vital organ of my own) like a protective talisman. At least I’m not writing on an iPad.

Even in a society that reveres digital technology, it is rather surprising how delicately, almost timidly, the entire topic has been handled in the press, and how little editorial cross-talk there has been among bio-ethicists, medical professionals, and cultural commentators. There is clearly fear of inviting discussion about the medical or social merits of the case for transplant when the patient is one of society’s most important members as well as one of its most wealthy. In a Medscape commentary from the Cleveland Clinic, John Marshall used the topic as an opportunity to laud our growing ability to differentiate among different kinds of tumors, consigning the transplantation debate to a small parenthesis.

Monday, September 12, 2011

Pharma on Facebook: The handwriting on the wall is about more than adverse-event reporting

A bad case of “consumer package goods envy”

Pharmaceutical companies have long had a bad case of “CPG envy” because regulatory handcuffs constrain their customer outreach and limit their ability to develop brand relationships with any of their customers. Even in this golden age of “patient democracy,” pharma has no small challenge engaging with patients for a complex set of reasons – among them the rather frustrating truth that patients don’t generally care to love and know their drug brand in quite the same way they love their brand of beer. (More on that in another entry…) At the same time, pharmaceutical companies feel a pressing need to cultivate relationships with patients as a result of many factors that are redirecting their marketing efforts toward end-users – including tighter access to physicians, the coming shift in pay burden to patients, and the industry’s focus on revenue lost through non-adherence.

For that reason, the opportunity for pharma companies to talk to patients and potentially hear them talk back through social media was hard to resist – especially given FDA’s continuing refusal to offer guidance – until Facebook announced new rules of the game requiring that everything be said out loud. Companies began rather quickly to reexamine their strategy and, in some cases, shut down the conversation.

Thursday, August 25, 2011

Generic Oncology Drug Shortage Means Unintended Healthcare Rationing

In cancer therapy, expensive drugs extend lives, while some cheap drugs save them.

Renowned oncologist and bio-ethicist Ezekiel J. Emanuel, MD, PhD inaugurated a regular New York Times op-ed gig earlier this month with commentary on generic cancer drug shortages.

Taking up a topic that has already been much discussed in both the professional media and the lay press, Emanuel observed that these drug shortages appear “to be the consequence of corporate decisions to cease production, or interruptions in production caused by money or quality problems, which manufacturers do not appear to be in a rush to fix.”

The gravity of this situation is widely acknowledged throughout the medical community. Dr. Hagop Kantarjian of the MD Anderson Cancer Center has gone so far as to observe that, in his opinion, the shortages of cytarabine have “affected life and death situations in the United States.”

Monday, August 1, 2011

Helping Patients Assess the Benefits of their Drugs: Reading Inside the Box and Between the Lines on Drug Efficacy

Nothing creates advertising memes faster than DTC promotion – not even Super Bowl commercials – because health professionals and “civilians” alike take prurient interest in the conversation between pharmaceutical companies and patients. It’s not surprising, then, that Rx drug ads are both the inspiration for cultural jokes (can anyone look at a claw-foot bath tub without thinking of erectile dysfunction?) and the launch point for serious public health commentary.

Case in point. In a recent op-ed article in the NY Times, “Think inside the box,” authors, Steven Woloshin and Lisa M. Schwartz, two Dartmouth Medical School professors, urge use of patient Fact Boxes that feature not just drug side effects but also data on efficacy – which, in many cases, turn out to be less impressive than what optimistic patients imagine them to be. The presumption, which seems hard to refute, is that patients can make more educated choices about the risk-benefits of drugs when they know more – not just about the risks, but also about the benefits, or lack thereof.

Friday, July 8, 2011

The New “Political” Science: Avastin Breast Cancer Debate Exposes Paradox and Contradictions

The FDA’s recommendation to rescind Avastin’s metastatic breast cancer indication provoked a mix of commentary, commendations, and outcry from across the spectrum of stakeholders with an interest in the decision – and in what the decision might mean for the future: the future of cancer therapy approvals, evidence-based medicine, coverage for off-label use, drug pricing, and healthcare rationing … among other things.

This debate lies at the center of a tangled web of science, psychology, politics, economics, and ethics. Science and psychology, in particular, collide here in a way that reminds us of the challenge of selling the public on evidence-based medicine.

We are built by evolution to see cause-and-effect. The subset of women with metastatic breast cancer who have done well on Avastin almost cannot help but believe that they have done well because of Avastin. And it is no easy thing to overcome this built-in visceral conviction with the dry logic of rationality or the weight of evidence from patients treated in groups rather than as individuals.

Friday, June 24, 2011

Whipsawed by the Long Tail: How Patient Advocacy Groups May Distort Our View of Patient Customers

Advocacy groups are vocal and powerful, and you don’t want them working against you. But they don’t necessarily have the same perspectives or agendas as less connected patients.

The industry began looking tentatively at patients as customers two decades ago but it is only since the Web created virtual disease communities that we’ve been able to find and talk with patients who have obscure diseases. This is occurring just as the industry is, ironically, being forced to look for new commercial opportunities in diseases that were once regarded as not profitable enough to target in the old industry block-buster model.

The list of patient advocacy groups is long and growing now that the Web has enabled patients with exceedingly rare diseases -- for example, alpha-1 antitrypsin deficiency or rasopathies -- to assemble and find their collective voice. Current estimates place the number of “rare” diseases at about 6,000 (JAMA, June 8, 2011).